ReviewCardiorenal medicine2026
Potential Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors in Regulating Cardiac and Renal Fibrosis.
Review in Cardiorenal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of agents initially developed for glycemic control in type 2 diabetes mellitus. Beyond their glucose-lowering effects, accumulating clinical evidence has demonstrated significant cardiorenal protective benefits in patients with chronic kidney disease (CKD), irrespective of diabetic status. Cardiac and renal fibrosis are central pathological processes contributing to CKD progression and cardiovascular dysfunction. However, the mechanisms underlying the anti-fibrotic effects of SGLT2 inhibitors remain incompletely understood. SUMMARY: This review summarizes current experimental and clinical evidence regarding the role of SGLT2 inhibitors in modulating cardiac and renal fibrosis. We discuss their potential mechanisms, including hemodynamic regulation, metabolic reprogramming, attenuation of oxidative stress and inflammation, inhibition of pro-fibrotic signaling pathways, and modulation of cellular crosstalk within the cardiorenal axis. Emerging insights from molecular and translational studies are integrated to clarify how SGLT2 inhibitors may exert anti-fibrotic effects beyond glycemic control. KEY MESSAGES: SGLT2 inhibitors confer cardiorenal protection that extends beyond glucose lowering and involves multifaceted anti-fibrotic mechanisms. Understanding these molecular and cellular pathways may provide new therapeutic perspectives for targeting fibrosis in CKD and cardiovascular disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.